<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247010</url>
  </required_header>
  <id_info>
    <org_study_id>Radium-Trombocyt</org_study_id>
    <nct_id>NCT03247010</nct_id>
  </id_info>
  <brief_title>Bone Marrow Suppression and Recovery During Radionuclide Treatment</brief_title>
  <official_title>Characterization of Bone Marrow Suppression and Recovery During Radionuclide Treatment Using Functional Tests of Thrombocytes and Hemostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radium-223-dichloride is approved therapy for patients with metastatic castration-resistant&#xD;
      prostate cancer and bone metastases. More than 20 % of patients treated at Rigshospitalet&#xD;
      develop bone marrow suppression as a side effect to Radium therapy The aim of the study is to&#xD;
      examine biomarkers of bone marrow suppression and recovery during Radium therapy as well as&#xD;
      markers of bone remodeling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radium-223-dichloride is approved therapy for patients with metastatic castration-resistant&#xD;
      prostate cancer and bone metastases. Therapy is administered intravenously every 4 weeks for&#xD;
      up to 6 cycles. More than 20 % of patients treated at Rigshospitalet develop bone marrow&#xD;
      suppression as a side effect to Radium therapy, which delays or excludes the patient from&#xD;
      further oncological therapy. Especially thrombocytopenia is a frequent side-effect and can be&#xD;
      long lasting.&#xD;
&#xD;
      The aim of the study is to examine whether biomarkers of bone marrow recovery (immature&#xD;
      platelets, platelet volume, reticulocytes, red cell distribution width) can predict&#xD;
      development of hematological toxicity during Radium therapy. Furthermore, to investigate&#xD;
      whether these biomarkers can predict recovery from toxicity in patients who develop bone&#xD;
      marrow suppression during therapy.&#xD;
&#xD;
      A secondary aim of the study is to evaluate whether dynamics in biomarkers of bone remodeling&#xD;
      during Radium therapy is correlated to overall survival and time to symptomatic skeletal&#xD;
      event. Optimally these biomarkers can aid in monitoring therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombocytopenia</measure>
    <time_frame>Within 1 year from inclusion</time_frame>
    <description>CTCAE grade 1-5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leucopenia</measure>
    <time_frame>Within 1 year from inclusion</time_frame>
    <description>CTCAE grade 1-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia</measure>
    <time_frame>Within 1 year from inclusion</time_frame>
    <description>CTCAE grade 3-5</description>
  </secondary_outcome>
  <enrollment type="Actual">68</enrollment>
  <condition>Castration-resistant Prostate Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood samples are taken before each cycle of Radium 223</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic castration-resistant prostate cancer, who initiate therapy with&#xD;
        Radium-223 at Rigshospitalet, Copenhagen, Denmark&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic castration resistant prostate cancer&#xD;
&#xD;
          -  Planned to initiate Radium therapy&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Able to understand study protocol and give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jann Ø Mortensen, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine &amp; PET</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Marie Øbro Fosbøl</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

